Ceva Animal Health, a leading global animal health player with a presence in 110 countries, announced that it has unveiled its latest investment in European vaccine manufacturing with the construction of a new facility in Hungary, expanding the capacity of Ceva Phylaxia.

With more than a century of expertise, Ceva Phylaxia works to combat major livestock diseases through innovative research and vaccine development.

This development will establish a 7,000 sq. m plant in Monor, Hungary, with the most advanced technologies, where Ceva will produce fermentation-based multicomponent inactivated vaccines for animals.

With this investment, the company said it will produce more than 8 billion doses of vaccines in the new manufacturing plant annually, on top of other animal health products.

“Building a new facility is always a significant milestone in the life of a company. In Hungary, we already benefit from a strong historical expertise with our Ceva Phylaxia campus. With the addition of this new production unit in Monor, we aim to create new synergies to advance preventive medicine,” said Marc Prikazsky, chairman and chief executive officer of Ceva Animal Health. “This project reflects our commitment to supporting farmers worldwide by developing tailored solutions to tackle emerging diseases and new variants. It embodies our ambition to build a promising future for our company, employees and partners, both in Hungary and internationally, while strengthening our research and development capabilities.”

Related:Oklahoma detects bird flu in domestic flock

The new plant is scheduled to start operations at the end of 2026.

For over 20 years, Ceva has been a strong advocate for prevention through vaccination, heavily investing in preventive medicine to significantly improve the health of husbandries but also to fight zoonotic and emerging diseases, contributing to preparation for future pandemics, the announcement said. Today, 54% of Ceva’s research and development budget is dedicated to vaccine development, and the company provides more than 50 vaccines to fight 19 zoonotic diseases.

Ceva pointed to its achievements that include developing an mRNA platform for animals in less than three years and status as a global leader in vector vaccines for poultry and also in broiler and hatchery vaccination. The company noted it also has global expertise in autogenous vaccines.

Led by experienced veterinarians whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being, Ceva’s portfolio includes preventive medicine such as vaccines and animal welfare products, pharmaceutical solutions for farm and companion animals, as well as providing equipment and services to its customers.

Related:Farmer optimism following election hits highest level in years